JPWO2021091585A5 - - Google Patents

Claims (6)

19. A compound according to claim 17 or 18 for use in a method of treating pain, cough, itch or neuroinflammatory disorders in a patient comprising administering to the patient an effective amount of a compound according to claim 1. pharmaceutical composition of The pain is back and neck pain, lower back pain, cancer pain, gynecological and labor pain, fibromyalgia, arthritis, rheumatoid arthritis, osteoarthritis, rheumatic pain, orthopedic pain, acute Postherpetic neuralgia and other neuropathic pain (including peripheral neuropathy), sickle cell disease, vulvar pain, perianal pain, irritable bowel disease, irritable bowel syndrome, inflammatory bowel disease, oral mucositis, esophagitis, interstitial Qualitative cystitis, urethritis and other urological pain, toothache, headache, trigeminal neurotrophic syndrome, erythromelalgia, abdominal wall pain, chronic abdominal wall pain, allergic rhinitis, myalgia, rectum pain, levator ani syndrome, transient rectal pain, hemorrhoidal pain, stomach pain, skin ulcer, gastric ulcer, burn pain, eye sensitivity, conjunctivitis (e.g. allergic conjunctivitis), eye redness, dry eye, dry eye syndrome (chronic ocular pain), complex regional pain syndrome, post-surgical ocular pain, post-operative pain, acute post-operative pain, and procedural pain (i.e. injections, abscess drainage, surgery, dental procedures, eye procedures, eye sensitivity, conjunctivitis (e.g. allergic conjunctivitis), eye redness, dry eyes, arthroscopy and other medical device use, cosmetic surgery, dermatological procedures, bone fractures 20. The pharmaceutical composition according to claim 19, selected from the group consisting of pain for induration, pain associated with biopsies, etc.). the cough is asthma, COPD, asthma-COPD overlap syndrome (ACOS), interstitial pulmonary fibrosis (IPF), idiopathic pulmonary fibrosis, postviral cough, postinfectious cough, chronic idiopathic cough and 20. The pharmaceutical composition according to claim 19, selected from the group consisting of cough in patients with lung cancer. The itch is pruritus, brachioradialis pruritus, chronic idiopathic pruritus, genital/anal pruritus, back paresthesia, scalp pruritus, allergic dermatitis, contact dermatitis, atopic dermatitis, hands Itching due to eczema, poison ivy, infections, parasites, insect bites, pregnancy, metabolic disorders, liver or kidney failure, drug reactions, allergic reactions, eczema, genital and anal itching, hemorrhoids, and cancer 20. The pharmaceutical composition of claim 19, selected from the group consisting of The neuroinflammatory disorder is allergic inflammation, asthma, chronic cough, conjunctivitis, rhinitis, psoriasis, inflammatory bowel disease, interstitial cystitis, arthritis, colitis, contact dermatitis, diabetes, eczema, cystitis , gastritis, migraine, rosacea, sunburn, pancreatitis, chronic rhinosinusitis, traumatic brain injury, polybacterial sepsis, tendon disorders, chronic urticaria, rheumatic disease, acute lung injury, irritation 20. The pharmaceutical composition of claim 19, selected from the group consisting of exposure to substances, irritants, pollutants, inhalation of chemical warfare agents, and atopic dermatitis. 20. A pharmaceutical composition according to claim 19, wherein the compound of formula (I) is used in combination with one or more exogenous large pore receptor agonists.